Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin of 15.8% and non-GAAP operating ...

and One contingent value right (each, a "CVR"), which is contingent on the sale of Till’s 33.3% ownership of IG Far East LLC (the "Contingent Event"), which will be eligible to convert into an ...

Stockholders are being offered an upfront payment of $3.00 per share in cash, plus a contingent value right (CVR) of $6.84 per share in cash, which is payable upon the achievement of a specific ...

Adjusted EBITDA of $14 million, compared to Adjusted EBITDA of $4 million in the first quarter of 2024 Based on information ...

Under the terms of the merger agreement, stockholders will receive an upfront payment of $3.00 per share in cash and a contingent value right (CVR) of $6.84 per share in cash payable upon ...

Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million, adjusted non-GAAP EBITDA of $195.0 ...

Regulator grills company over its US$41 million acquisition of Empire Resorts from Genting group’s founding Lim family.

Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for ...

Kronos Bio, Inc. (NASDAQ: KRON)’s sale to Concentra Biosciences, LLC for $0.57 in cash per share plus one non-tradeable contingent value right. If you are a Kronos shareholder, click here to ...

Kronos Bio, Inc. (NASDAQ: KRON)’s sale to Concentra Biosciences, LLC for $0.57 in cash per share plus one non-tradeable contingent value right. If you are a Kronos shareholder, click ...